Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Deals Of The Week: Can Endo Succeed By Copying The Valeant Model?

Executive Summary

NuPathe and its migraine patch product Zecuity are the latest acquisition by Endo since former Valeant executive Rajiv De Silva moved into the chief executive’s office – will he succeed in bringing his former company’s model to the specialty firm? Plus, Valeant made its own news during the week, while AstraZeneca bought out Bristol’s share of their diabetes joint venture, and more.

You may also be interested in...



Teva Wins Bidding For NuPathe And Its Migraine Patch, Topping Endo

Teva will be responsible for launching the Zecuity migraine patch after acquiring NuPathe for $144 million upfront. Teva’s $3.65 per share offer for NuPathe trumps Endo’s $2.85 per share, or $105 million, offer.

AZ Doubles Down On Diabetes, Buys Out Bristol’s Share in Alliance

AstraZeneca will acquire all of Bristol’s interests in their current diabetes alliance. In doing so, AZ believes its geographic reach and scale in assets and capabilities position it to succeed, while Bristol retreats from diabetes to focus on specialty biologics, notably its PD-1 franchise.

Merck Bets Big On Oncology In New R&D Strategy

The big pharma will establish a new oncology unit focused on bringing its anti-PD-1 immunotherapy MK-3475 to market as part of a massive R&D overhaul aimed at lowering costs while driving innovation. Merck isn’t one of the industry’s leading oncology players and may not have as much R&D expertise in the area as rivals, but it might not ultimately matter – as long as MK-3475 gets to market.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

PS055828

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel